Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Collagenolytic activity by malignant tumours.

R L O'Grady, P J Harrop, D A Cameron

    Pathology
    |April 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study.

    ESMO open·2021
    Same author

    Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2020
    Same author

    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same author

    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same journal

    Impact of the 2025 Endocrine Society clinical practice guideline on the diagnosis and management of primary aldosteronism for the clinical laboratory.

    Pathology·2026
    Same journal

    Cribriform intraductal carcinoma of the prostate may have a greater prognostic impact even than Gleason grade 5 conventional prostatic adenocarcinoma.

    Pathology·2026
    Same journal

    Bordetella pertussis: emerging epidemiology, diagnosis and management.

    Pathology·2026
    Same journal

    Development and validation of a real-time polymerase chain reaction for the detection of Haycocknema perplexum.

    Pathology·2026
    Same journal

    Recent advances in the understanding of TP53 in haematological malignancies.

    Pathology·2026
    Same journal

    Concurrent renal amyloid light chain amyloidosis, light chain crystalline podocytopathy and light chain proximal tubulopathy: a case report.

    Pathology·2026
    See all related articles

    Malignant tumors, particularly carcinomas, produce collagen-degrading enzymes. These enzymes, active in vitro, may contribute to tumor invasion in vivo, highlighting a key difference from normal cells.

    Area of Science:

    • Biochemistry
    • Oncology
    • Cell Biology

    Background:

    • Collagenolysis, the breakdown of collagen, is crucial in tissue remodeling and disease.
    • Tumor invasion involves the degradation of the extracellular matrix, including collagen.

    Purpose of the Study:

    • To investigate the production of neutral proteases capable of collagen digestion by carcinomas and sarcomas.
    • To compare the collagenolytic activity of malignant tumor cells with normal fibroblasts.

    Main Methods:

    • Investigated five carcinomas and five sarcomas for neutral protease production.
    • Analyzed collagenolytic activity in neoplastic cell extracts, culture media, and mixed cell cultures.
    • Compared enzyme activity in tumor cells versus normal fibroblasts, assessing activation potential.

    Related Experiment Videos

    Main Results:

    • Carcinomas exhibited significantly higher collagenolytic activity than sarcomas.
    • All investigated malignant tumors produced enzymes capable of in vitro collagenolysis.
    • Tumor-derived collagenolytic enzymes were active without needing activation (trypsin or APMA), unlike those from normal fibroblasts.

    Conclusions:

    • Malignant tumors, especially carcinomas, possess significant in vitro collagenolytic ability.
    • The active collagenolytic enzymes produced by tumor cells may play a role in their invasive behavior in vivo.
    • This enzymatic activity distinguishes tumor cells from normal fibroblasts.